Crossmark

Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy

Crossref DOI link: https://doi.org/10.1007/s00280-025-04773-w

Published Online: 2025-04-10

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gehr, Nina Lykkegaard

Mortensen, Christina

Stage, Tore B.

Pedersen, Malene Roland Vils

Rafaelsen, Søren Rafael

Madsen, Jonna Skov

Olsen, Dorte Aalund

Timm, Signe

Jensen, Lars Henrik

Hansen, Torben Frøstrup

Finnerup, Nanna Brix

Ventzel, Lise
Funding

Funding for this research was provided by:

Aarhus Universitet
License Information

Text and Data Mining valid from 2025-04-10

Version of Record valid from 2025-04-10
More Information

Article History

Received: 31 October 2024

Accepted: 18 March 2025

First Online: 10 April 2025

Declarations

:

: NBF has received consultancy fees from PharmNovo, Vertex, NeuroPN, Saniona, Nanobiotix, and Neurvati, and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics outside the submitted work. She has received grants from IMI2PainCare an EU IMI 2 (Innovative medicines initiative) public-private consortium and the companies involved are: Grunenthal, Bayer, Eli Lilly, Esteve, and Teva, outside the submitted work. TBS has given paid lectures for Pfizer and Eisai and done consulting for Pfizer, and collaborated with Novo Nordisk A/S, all unrelated to the work reported in the present paper.

Document is current

Any future updates will be listed below